CAS 3033586-31-8

2-Pyrrolidinecarboxamide, 1-[(2S)-2-[4-[trans-4-[[4-(4′-chloro-5′-oxospiro[cyclohexane-1,7′(5′H)-indolo[1,2-a]quinazolin]-10′-yl)-1-piperidinyl]methyl]cyclohexyl]-1H-1,2,3-triazol-1-yl]-3,3-dimethyl-1-oxobutyl]-4-hydroxy-N-[(1R)-1-[4-(4-methyl-5-thiazolyl)phenyl]-2-(4-morpholinyl)ethyl]-, (2S,4R)-

Description:

2-Pyrrolidinecarboxamide, with the CAS number 3033586-31-8, is a complex organic compound characterized by its intricate molecular structure, which includes multiple functional groups such as amides, triazoles, and various cyclic moieties. This compound features a pyrrolidine ring, which contributes to its potential biological activity, and a carboxamide group that may enhance solubility and reactivity. The presence of a chloro-substituted spirocyclic structure and a thiazole moiety suggests potential pharmacological properties, possibly in the realm of medicinal chemistry. Additionally, the compound's stereochemistry, indicated by the (2S,4R) configuration, plays a crucial role in its biological interactions and efficacy. Overall, this substance may exhibit significant interest for research in drug development, particularly due to its diverse structural components that could interact with various biological targets. However, detailed studies would be necessary to elucidate its specific properties, mechanisms of action, and potential applications in therapeutic contexts.

Formula: C₆₁H₇₅ClN₁₀O₅S

Synonyms:

• 2-Pyrrolidinecarboxamide, 1-[(2S)-2-[4-[trans-4-[[4-(4′-chloro-5′-oxospiro[cyclohexane-1,7′(5′H)-indolo[1,2-a]quinazolin]-10′-yl)-1-piperidinyl]methyl]cyclohexyl]-1H-1,2,3-triazol-1-yl]-3,3-dimethyl-1-oxobutyl]-4-hydroxy-N-[(1R)-1-[4-(4-methyl-5-thiazolyl)phenyl]-2-(4-morpholinyl)ethyl]-, (2S,4R)-

SMD-3236

CAS: 3033586-31-8

SMD-3236 is a PRAOTAC degrader targeting SMARCA2, designed using SMARCA ligand and VHL-1 ligand, and exhibits prolonged anti-tumor activity in vivo. SMARCA2 acts as a synthetic lethal target in cancer cells lacking SMARCA4, with SMD-3236 showing 2000-fold selectivity for SMARCA2 over SMARCA4, having a DC50 of less than 1 nM and a Dmax of over 95%. In the human cancer xenograft models deficient in SMARCA4, notably the H838 model, SMD-3236 effectively induces loss of SMARCA2 in tumor tissue while sparing the SMARCA4 protein, thereby inhibiting tumor growth. The compound consists of a target protein ligand (red part) SMI-1074, a PROTAC linker (black part) (trans-4-Ethynylcyclohexyl)methyl methanesulfonate, and an E3 ligase ligand (blue part) SMARCA2 ligand-14, forming the E3LigaseLigand-linker Conjugate 159.

Formula: C₆₁H₇₅ClN₁₀O₅S

Color and Shape: Solid

Molecular weight: 1095.83

Ref: TM-T205371